• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Additional aromatase inhibitor may improve endometrial cancer chemotherapy effectiveness

byMonica ParksandDavid Wang
February 3, 2015
in Obstetrics, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In a phase II trial of 35 women with advanced endometrial cancer, combination therapy with aromatase inhibitor (letrozole) and mTOR inhibitor (everolimus) demonstrated a high clinical benefit rate.

Evidence Rating Level: 2 (Good)

Study Rundown: Endometrial cancer (EC) is the most common gynecological malignancy in the United States with over 52 000 cases diagnosed in 2014. Previous studies have noted an association between dysregulation of the phosphoinositol-3 kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway with poorer prognosis in EC patients. Estrogen receptor (ER) signaling have been shown to cross-regulate the PI3K/mTOR signaling pathway and may provide a potential target for mTOR signaling inhibition. The purpose of this phase II clinical trial was to evaluate the response of a combination therapy of an aromatase inhibitor (letrozole) and PI3K/mTOR inhibitor (everolimus) in patients with recurrent EC. Overall, 35 patients with recurrent/metastatic EC were treated with the combination therapy. At the conclusion of the trial, the combination treatment demonstrated a clinical response rate of 40% at 16 weeks, as measured by prolonged stable disease. The safety profile of this combination was excellent as there were no patients that discontinued treatment due to toxicity. The most significant predictor of response were patients with endometrioid histology. The results of this trial support the use of everolimus and letrozole in women with advanced endometrioid EC. However, this was only a phase II trial with a small sample size; additional larger randomized controlled trials are required to accurately describe the efficacy of this combination treatment.

Click to read the study in JCO

Relevant Reading: A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma.

In-Depth [prospective cohort]: This clinical trial was a phase II, open-labelled, multi-centered trial to determine the effectiveness of the combination therapy of letrozole and everolimus in patients with advanced EC. Overall, 35 patients (median age 62 years; range: 24-82 years) with progressive or recurrent EC were recruited to receive daily doses of oral letrozole and everolimus for 4 week cycles. The primary end point was clinical benefit rate (CBR), defined as complete response, partial response, or stable disease for 16 weeks or more. After a median follow-up of 14 months, the CBR was 40% (14 patients) at 16 weeks with a median number of cycles of 15 (range: 7-29 cycles). Twenty percent of patients discontinued treatment after prolonged complete response. The most common side-effects included fatigue (74%), hypercholesterolemia (71%), and mucositis (66%); no patients discontinued treatment due to adverse events. The median overall survival time was 14 months (95% CI: 9.5 to 24.4 months). Patients with endometrioid histology demonstrated significantly increased CBR compared to patients with serous histology (37.5% vs 0%; p<0.0092).

RELATED REPORTS

Lenvatinib plus pembrolizumab not associated with improved survival compared to standard therapy for recurrent endometrial cancer

GSK’s Jemperli in combination with chemotherapy shows improved overall survival in patients with endometrial cancer.

#VisualAbstract: Atezolizumab and Chemotherapy Improve Outcomes in Advanced or Recurrent Endometrial Cancer

More from this author: Rituximab linked with reduced chronic immune disease following stem cell transplantation, High-dose prophylaxis for hemophilia increases costs with minimal benefit, Ambrisentan found ineffective against idiopathic pulmonary fibrosis

Image: PD

©2014 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: aromatase inhibitorendometrial cancer
Previous Post

2 Minute Medicine Rewind January 26 – February 1, 2015

Next Post

Increasing proxy-reported pain at end-of-life from 1998-2010

RelatedReports

Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial
Obstetrics

Lenvatinib plus pembrolizumab not associated with improved survival compared to standard therapy for recurrent endometrial cancer

March 20, 2025
American-born Asian women more likely to have endometrial cancer
Pharma

GSK’s Jemperli in combination with chemotherapy shows improved overall survival in patients with endometrial cancer.

August 15, 2024
#VisualAbstract: Atezolizumab and Chemotherapy Improve Outcomes in Advanced or Recurrent Endometrial Cancer
StudyGraphics

#VisualAbstract: Atezolizumab and Chemotherapy Improve Outcomes in Advanced or Recurrent Endometrial Cancer

August 14, 2024
American-born Asian women more likely to have endometrial cancer
Oncology

The addition of cisplatin to standard-of-care radiation therapy does not appear to improve progression-free survival for patients with localized recurrent endometrial cancer.

April 29, 2024
Next Post
Increasing proxy-reported pain at end-of-life from 1998-2010

Increasing proxy-reported pain at end-of-life from 1998-2010

Vaccines for predicted influenza strains may provide wide protection [PreClinical]

Oseltamivir (Tamiflu) reduces duration of influenza symptoms, respiratory complications, and hospital admissions

Smokeless tobacco use in children has not changed

Financial incentives improve smoking cessation rates in pregnant women

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sodium-glucose cotransporter 2 inhibitors may decrease risk of serious liver events in patients with cirrhosis
  • #VisualAbstract: Lactated Ringer’s Solution Does Not Improve Outcomes Relative to Normal Saline
  • 2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.